Severity of pain. Pain, unspecified
Conditions
Interventions
Intervention 1: Intervention group: 50 micrograms of neostigmine (manufactured by Subhan Pharmaceutical Company, Iran) plus 2.5 cc bupivacaine (manufactured by Elixir Pharmaceutical Company, Iran) 5%
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Women who had an elective cesarean delivery Women who are between 18 and 50 years old.
Exclusion criteria
Exclusion criteria: Patients who refused to participate, or after spinal anesthesia, the required sensory level was not established and were then subjected to general anesthesia. Patients with a history of allergy to any of the drugs used in this research History of drug addiction Moderate or severe heart, kidney, lung or nervous diseases Significant scoliosis or kyphosis Excessive obesity Blood coagulation disease Patients with height less than 130 cm or BMI more than 35
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intensity of pain. Timepoint: 0, 2, 4, 8 and 12 hours. Method of measurement: Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sedation rate. Timepoint: Hours 0, 2, 4, 8 and 12. Method of measurement: Using the Ramsay scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGoli Azzi
Mazandaran University of Medical Sciences
Outcome results
None listed